The Impact of Collagenase Clostridium histolyticum Introduction on Dupuytren Treatment Patterns in the United States

• Published in: The Journal of hand surgery (American ed.) Vol. 41; no. 10; pp. 963 - 968
• Main Authors: Zhao, John Z., BA, Hadley, Scott, MD, Floyd, Emerson, BA, Earp, Brandon E., MD, Blazar, Philip E., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2016
• Subjects: Cohort Studies; Collagenase; Databases, Factual; Dupuytren; Dupuytren Contracture - diagnosis; Dupuytren Contracture - drug therapy; Dupuytren Contracture - epidemiology; Dupuytren Contracture - surgery; Female; Humans; Incidence; Injections, Intralesional; Male; Microbial Collagenase - therapeutic use; Orthopedics; Pain Measurement; Prognosis; Range of Motion, Articular - physiology; Retrospective Studies; Severity of Illness Index; Treatment Outcome; treatment patterns; United States - epidemiology; United States Food and Drug Administration; Dupuytren; Collagenase; treatment patterns
• ISSN: 0363-5023; 1531-6564
• DOI: 10.1016/j.jhsa.2016.07.090

Purpose The U.S. Food and Drug Administration approved the use of collagenase Clostridium histolyticum (CCH) in the United States in February 2010. This study addresses the impact of that approval on the number of Dupuytren contracture (DC) encounters and treatment patterns in the United States. Methods Using the Intercontinental Marketing Services Health Office-Based Medical Claims database, we identified the monthly number of DC encounters and DC procedures between January 2007 and December 2013. Collagenase Clostridium histolyticum usage data from March 2010 to December 2013 was derived from the U.S. CCH manufacturer’s data warehouse. Using the combined data, the yearly increasing trends in DC encounters and treatment volume were compared before and after the introduction of CCH. Time trends in the relative procedure frequencies were then examined. Finally, the presence of seasonal variation was tested for in each treatment type. Results Dupuytren contracture encounters increased on average by 19,015 per year between 2007 and 2009, whereas between 2011 and 2013, DC encounters increased on average by 34,940 per year. In terms of absolute procedure counts, the surgery trend line began decreasing in 2010 with the release of CCH. Meanwhile, CCH continuously increased between 2010 and 2013, and needle aponeurotomy (NA) remained relatively stable. By the year 2013, minimally invasive techniques (NA and CCH) comprised 39% of all treatment, compared with only 14% in 2007. Lastly, there was a statistically significant seasonal increase in the number of surgical procedures during the wintertime but no seasonal variation in NA or CCH. Conclusions After the introduction of CCH, the number of Dupuytren encounters increased at a greater annual rate. The introduction and growth of CCH coincided with a decrease in surgery. The number of NA procedures remained steady throughout the study period. The number of open surgery cases followed a predictable seasonal variation with more procedures during the winter months, but this seasonal variation was not seen with less invasive techniques. Type of study/level of evidence Economic/Decision Analysis II.